PRR7 Inhibitors
PRR7 inhibitors encompass a range of chemical entities that modulate synaptic signaling pathways in which PRR7 is a critical component. By blocking key enzymes such as kinases and phosphatases, these inhibitors can alter the phosphorylation dynamics crucial for PRR7's interaction with other synaptic proteins, thus reducing its functional role in signal transduction at synaptic sites. For instance, the inhibition of kinase activity can impede the phosphorylation events necessary for PRR7 to engage in its modulatory functions, while phosphatase inhibitors can disrupt dephosphorylation processes that are equally important for PRR7's activity. Moreover, the blockade of ion channels and receptors integral to synaptic transmission can indirectly limit the synaptic activity that PRR7 regulates, particularly affecting its potential involvement in synaptic plasticity. Inhibition of calcium/calmodulin-dependent processes specifically targets the interplay between PRR7 and calmodulin-dependent kinases, further influencing the synaptic functions of PRR7.
Furthermore, the chelation of intracellular calcium and the antagonism of receptors that mediate calcium-dependent neurotransmission can substantially diminish the role of PRR7 in calcium-related signaling events within the synapse. Inhibitors that affect the metabolism of phosphoinositides also have the potential to decrease PRR7's participation in the corresponding signaling cascades, thereby attenuating its role in synaptic transmission and plasticity. By diminishing the activity of protein kinases such as CaMKII and PKA, which are pivotal in synaptic modulation, these inhibitors can further impair the synaptic influence of PRR7.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent kinase inhibitor that by inhibiting phosphorylation events can interfere with PRR7 protein-protein interactions at synaptic sites, leading to decreased functional activity of PRR7 in signal transduction mechanisms. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $163.00 $300.00 $1642.00 | 18 | |
Calmodulin antagonist that interferes with calcium/calmodulin-dependent processes, potentially reducing PRR7 interaction with calmodulin-dependent kinases and thus its synaptic functions. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Phosphoinositide 3-kinases (PI3K) inhibitor, which could affect downstream signaling pathways including those involving PRR7, leading to a decreased role in synaptic signaling and plasticity. | ||||||
D(−)-2-Amino-5-phosphonovaleric acid (D-AP5) | 79055-68-8 | sc-200434 | 5 mg | $95.00 | 2 | |
NMDA receptor antagonist that may reduce synaptic transmission and plasticity where PRR7 is implicated in modulating these processes. | ||||||
BAPTA, Free Acid | 85233-19-8 | sc-201508 sc-201508A | 100 mg 500 mg | $67.00 $262.00 | 10 | |
Calcium chelator that may decrease intracellular calcium levels, potentially affecting PRR7's interaction with calcium-binding proteins and its role in calcium-dependent synaptic plasticity. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Calcineurin inhibitor that may disrupt calcium/calmodulin-dependent dephosphorylation events, potentially influencing PRR7's activity in synaptic signaling pathways where phosphorylation status is critical. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
Inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII), potentially limiting PRR7's ability to interact with CaMKII-dependent signaling pathways involved in synaptic modulation and plasticity. | ||||||
KT 5720 | 108068-98-0 | sc-3538 sc-3538A sc-3538B | 50 µg 100 µg 500 µg | $97.00 $144.00 $648.00 | 47 | |
Inhibitor of protein kinase A (PKA) which may reduce the phosphorylation of proteins involved in synaptic transmission, potentially affecting PRR7's activity in PKA-dependent signaling pathways. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $199.00 $460.00 $1479.00 | 1 | |
P2X1 purinoceptor antagonist that may disrupt ATP-mediated synaptic signaling, potentially affecting the functional activity of PRR7 in purinergic signaling pathways at synaptic junctions. | ||||||